Summary of Neurocrine Biosciences (NBIX) Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: Over $950 million for Q2 2026, representing nearly 40% year-over-year growth.

Non-GAAP EPS: $2.85 per share.

Product Sales:

INGREZZA: $716 million, up 15% year-over-year.

CRENESSITY: $184 million, reflecting strong launch execution.

VYKAT XR: Pro forma net sales of $94 million, with $54 million recognized post-acquisition.

Pro forma Total Revenues: $998 million when including full quarter VYKAT XR sales.

Cash Position: Approximately $500 million in cash with no debt.

2Strategic Updates and Business Highlights

Diversified Portfolio: The company has transitioned from a single product focus to multiple growth drivers, including INGREZZA, CRENESSITY, and VYKAT XR.

Acquisition of VYKAT XR: Successfully integrated into the portfolio, expected to drive sequential growth.

Pipeline Development: Progressing towards multiple clinical milestones in 2027, including Phase 3 data readouts for osavampator (major depressive disorder) and dereclidine (schizophrenia).

Promotions: Samir Siddhanti promoted to Chief Business Officer, reflecting the company's commitment to strategic growth.

3Forward Guidance and Outlook

INGREZZA Guidance: Full-year revenue guidance raised to a range of $2.825 billion to $2.875 billion, indicating approximately 13% year-over-year growth.

VYKAT XR Expectations: Anticipated sequential growth as integration progresses, with a focus on expanding the prescriber base and patient access.

Clinical Milestones: Confident in upcoming Phase 3 data readouts, which are expected to bolster the company's growth trajectory.

4Bad News, Challenges, or Points of Concern

VYKAT XR Discontinuations: Initial discontinuation rates are tracking as expected but may impact short-term sales growth.

Competitive Landscape: Concerns regarding pricing dynamics and competitive pressures from other VMAT inhibitors, particularly AUSTEDO, which has been performing strongly in the market.

Market Penetration: While CRENESSITY is growing, there remains a significant portion of the target prescriber base that has yet to adopt the product, indicating potential barriers to broader market penetration.

5Notable Q&A Insights

Pricing Dynamics: Management is optimistic about maintaining access and pricing stability for INGREZZA, with ongoing discussions with payers.

CRENESSITY Growth: The growth is characterized as steady, with no significant one-time issues affecting Q2 performance. The focus remains on expanding the prescriber base and increasing repeat prescriptions.

VYKAT XR Strategy: The team is focused on educating providers and managing patient expectations regarding treatment timelines and side effects.

Pipeline Confidence: The company is encouraged by the feedback on CRENESSITY's long-term safety profile and efficacy, which is expected to support continued adoption.

Future Infrastructure: Neurocrine is well-positioned to launch new products, leveraging its existing commercial foundation, particularly for osavampator and dereclidine. Overall, Neurocrine Biosciences reported strong financial performance in Q2 2026, driven by a diversified portfolio and strategic acquisitions, while also facing challenges in market penetration and competitive pressures. The outlook remains positive with significant clinical milestones on the horizon.